{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:12:43Z","timestamp":1777896763632,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omtn.2020.12.004","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T05:44:02Z","timestamp":1607579042000},"page":"476-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Designed U7 snRNAs inhibit\u00a0DUX4\u00a0expression and improve FSHD-associated outcomes in\u00a0DUX4\u00a0overexpressing cells and FSHD patient myotubes"],"prefix":"10.1016","volume":"23","author":[{"given":"Afrooz","family":"Rashnonejad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamhossein","family":"Amini-Chermahini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah K.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Wein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5135-4317","authenticated-orcid":false,"given":"Scott Q.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2020.12.004_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2020.12.004_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clineuro.2011.10.022","article-title":"Atypical onset in a series of 122 cases with FacioScapuloHumeral Muscular Dystrophy","volume":"114","author":"Pastorello","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.omtn.2020.12.004_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nmd.2006.06.008","article-title":"Severe phenotype in infantile facioscapulohumeral muscular dystrophy","volume":"16","author":"Klinge","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2020.12.004_bib4","first-page":"1916","article-title":"Facioscapulohumeral Muscular Dystrophy","volume":"22","author":"Statland","year":"2016","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.omtn.2020.12.004_bib5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtn.2020.12.004_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ng.3846","article-title":"Conservation and innovation in the DUX4-family gene network","volume":"49","author":"Whiddon","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib8","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/emboj.2008.201","article-title":"An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies","volume":"27","author":"Bosnakovski","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.omtn.2020.12.004_bib9","doi-asserted-by":"crossref","first-page":"18157","DOI":"10.1073\/pnas.0708659104","article-title":"DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1","volume":"104","author":"Dixit","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.12.004_bib10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22275","article-title":"DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in\u00a0vivo","volume":"69","author":"Wallace","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib11","doi-asserted-by":"crossref","first-page":"e123538","DOI":"10.1172\/jci.insight.123538","article-title":"AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD","volume":"3","author":"Giesige","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2020.12.004_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.nmd.2007.04.002","article-title":"The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein","volume":"17","author":"Kowaljow","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2020.12.004_bib13","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/hmg\/ddp180","article-title":"RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy","volume":"18","author":"Snider","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib14","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib15","doi-asserted-by":"crossref","first-page":"e1006658","DOI":"10.1371\/journal.pgen.1006658","article-title":"DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy","volume":"13","author":"Shadle","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2016.08.007","article-title":"DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients","volume":"99","author":"Dmitriev","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.omtn.2020.12.004_bib17","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib18","doi-asserted-by":"crossref","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.12.004_bib19","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib20","first-page":"4577","article-title":"Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4","volume":"25","author":"Eidahl","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/geno.1995.1166","article-title":"The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes","volume":"28","author":"Lyle","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.omtn.2020.12.004_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","article-title":"Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element","volume":"236","author":"Gabri\u00ebls","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.omtn.2020.12.004_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/genes8030093","article-title":"Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.omtn.2020.12.004_bib26","doi-asserted-by":"crossref","first-page":"eaay0271","DOI":"10.1126\/scitranslmed.aay0271","article-title":"Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy","volume":"12","author":"Lek","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2020.12.004_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mt.2015.200","article-title":"CRISPR\/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy","volume":"24","author":"Himeda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib28","doi-asserted-by":"crossref","first-page":"eaaw7099","DOI":"10.1126\/sciadv.aaw7099","article-title":"Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy","volume":"5","author":"DeSimone","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2020.12.004_bib29","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.12.004_bib30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1261\/rna.070177.118","article-title":"RNAscope in\u00a0situ hybridization-based method for detecting DUX4 RNA expression in\u00a0vitro","volume":"25","author":"Amini Chermahini","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2020.12.004_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD","volume":"8","author":"Wallace","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2020.12.004_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","article-title":"Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases","volume":"21","author":"Verma","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib33","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1073\/pnas.1200523109","article-title":"U7 small nuclear ribonucleoprotein represses histone gene transcription in cell cycle-arrested cells","volume":"109","author":"Ideue","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.12.004_bib34","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s00018-004-4190-0","article-title":"The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein","volume":"61","author":"Sch\u00fcmperli","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2020.12.004_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/mt.2009.113","article-title":"Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy","volume":"17","author":"Goyenvalle","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib36","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2012.26","article-title":"Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy","volume":"20","author":"Goyenvalle","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib37","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1038\/s41598-019-43964-3","article-title":"Restoration of correct \u03b2IVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in \u03b2-thalassaemia\/HbE erythroid cells","volume":"9","author":"Nualkaew","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2020.12.004_bib38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2020.12.004_bib40","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1093\/hmg\/dds284","article-title":"Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis","volume":"21","author":"Jones","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12883-019-1452-x","article-title":"Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study","volume":"19","author":"LoRusso","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib42","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","article-title":"Adding quantitative muscle MRI to the FSHD clinical trial toolbox","volume":"89","author":"Mul","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2020.12.004_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib44","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2020.12.004_bib46","first-page":"4419","article-title":"Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/hmg\/ddy400","article-title":"Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development","volume":"28","author":"van den Heuvel","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib48","doi-asserted-by":"crossref","first-page":"e64691","DOI":"10.1371\/journal.pone.0064691","article-title":"DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells","volume":"8","author":"Sharma","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.12.004_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.119.264689","article-title":"p38\u03b1 Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy","volume":"374","author":"Rojas","year":"2020","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JND-170233","article-title":"Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach","volume":"4","author":"Wein","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2020.12.004_bib51","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib52","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2020.12.004_bib54","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","article-title":"Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice","volume":"25","author":"Carrell","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib55","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","article-title":"Highly efficient in\u00a0vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice","volume":"22","author":"Aoki","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2020.12.004_bib56","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2020.12.004_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm9010001","article-title":"Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches","volume":"9","author":"Shimizu-Motohashi","year":"2019","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.omtn.2020.12.004_bib58","doi-asserted-by":"crossref","first-page":"e0121556","DOI":"10.1371\/journal.pone.0121556","article-title":"Cell membrane integrity in myotonic dystrophy type 1: implications for therapy","volume":"10","author":"Gonz\u00e1lez-Barriga","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2020.12.004_bib59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s000180300047","article-title":"U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping","volume":"60","author":"Brun","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2020.12.004_bib60","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1073\/pnas.0704977104","article-title":"U bodies are cytoplasmic structures that contain uridine-rich small nuclear ribonucleoproteins and associate with P bodies","volume":"104","author":"Liu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2020.12.004_bib61","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb.2571","article-title":"Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy","volume":"20","author":"Stadler","year":"2013","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120303851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120303851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:36:48Z","timestamp":1777624608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253120303851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":61,"alternative-id":["S2162253120303851"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2020.12.004","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designed U7 snRNAs inhibit\u00a0DUX4\u00a0expression and improve FSHD-associated outcomes in\u00a0DUX4\u00a0overexpressing cells and FSHD patient myotubes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2020.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}